Argos Therapeutics (ARGS) Misses Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Argos Therapeutics (ARGS) Misses Q2 EPS by 5c

Argos Therapeutics Reports Second Quarter 2016 Financial Results and Recent Operational Highlights

August 10, 2016 4:06 PM EDT

- Independent Data Monitoring Committee Recommended Continuation of Phase 3 ADAPT Trial of AGS-003 in Metastatic Renal Cell Carcinoma -

- Closed on $29.8 million Second Tranche of March 2016 Financing -

- Raised Gross Proceeds of $50.0 million in Follow-on Offering - 

- Entered into Strategic Research Agreement with Adaptive Biotechnologies -

- Company Added to the Russell 2000® Index -

- Conference Call and Webcast Today, August 10th, at 4:30 p.m. ET -

DURHAM, N.C., Aug. 10, 2016... More